Inhibition of Renal Fibrosis and Glomerular Injury by Sacubitril/Valsartan, a Combination Angiotensin Receptor Blocker and Neprilysin Inhibitor, in a Salt-Sensitive Hypertensive Model Using Angiotensin 1 Receptor Knockout Mice: The Contribution of Non-Angiotensin Blocking Effects to Renal Protection

Rei Otsu\textsuperscript{1}, Yoshiaki Taniyama\textsuperscript{1, 2,*}, Fumihiro Sanada\textsuperscript{1}, Jun Muratsu\textsuperscript{1, 2}, Kana Shibata\textsuperscript{1}, Tatsuya Fujikawa\textsuperscript{1}, Kanako May Brule\textsuperscript{1}, Hideo Shimizu\textsuperscript{1}, Hiromi Rakugi\textsuperscript{2} and Ryuichi Morishita\textsuperscript{1}

\textsuperscript{1}Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
\textsuperscript{2}Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan

Received: October 19, 2018 Revised: November 17, 2018 Accepted: November 20, 2018

Supplementary Material

Let us know if this is what you meant by the request.
We started an oral administration of Sac/Val (30-60 mg/kg/day) and valsartan (as a control group) (15-30 mg/kg/day) 7 days before administration of aldosterone and 1 % NaCl. Then, we prepared an aldosterone-sustained administration model using an osmotic pump, implanted all of the mice 7 days later and used an experimental system to approximate the aldosterone breakthrough model.